Anastrozole, letrozole and exemestane: oestrogen suppression research.
8 articles
PCT & Support
Testosterone maintains bone density through both direct AR-mediated osteoblast activation and indirect estradiol-mediated osteoclast suppression. Advanced research guide covering androgen effects on bone remodeling, the aromatization requirement, and compound research for osteoporosis models.
5 min read
PCT & Support
Aromatase is the enzyme responsible for estrogen biosynthesis from androgen precursors. Research guide covering CYP19A1 mechanism, tissue expression, role in androgen metabolism, aromatase inhibitor pharmacology, and why aromatization is a key variable in anabolic research models.
5 min read
PCT & Support
Anastrozole and exemestane both inhibit the CYP19A1 aromatase enzyme but through fundamentally different mechanisms — reversible binding vs. irreversible mechanism-based inactivation. Research comparison of pharmacology, enzyme kinetics, selectivity profiles, and bone effects for AI research compound selection.
4 min read
PCT & Support
Exemestane (Aromasin) is a steroidal, mechanism-based irreversible aromatase inhibitor. Unlike anastrozole and letrozole, exemestane permanently inactivates CYP19A1 by forming a covalent bond with the enzyme. Research profile covering mechanism, androgenic metabolites, and protocol applications.
6 min read
PCT & Support
Anastrozole (Arimidex) and letrozole (Femara) are both third-generation non-steroidal aromatase inhibitors, but differ in potency, pharmacokinetics, and optimal research applications. Research comparison guide for selecting the right AI.
6 min read
Peptides & Recovery
Post-cycle therapy (PCT) protocols use hCG, SERMs (tamoxifen, clomiphene), and aromatase inhibitors in sequence to restore hypothalamic-pituitary-testicular axis function after androgen suppression. Research guide to designing evidence-based PCT protocols.
7 min read
PCT & Support
Letrozole (Femara) is the most potent non-steroidal aromatase inhibitor available, achieving near-complete estradiol suppression. Research overview of its mechanism, pharmacokinetics, and use in androgen/estrogen research protocols.
5 min read
PCT & Support
Anastrozole (Arimidex) is a third-generation non-steroidal aromatase inhibitor (AI) that suppresses estradiol synthesis by competitively inhibiting CYP19A1. Research overview of its mechanism, PK, and use in androgen/estrogen research protocols.
5 min read
Hilma Biocare
Potent aromatase inhibitor. Studied for estrogen control during hormonal research.
99.3%· Janoshik
Hilma Biocare
Strong aromatase inhibitor. More potent estrogen suppression than Anastrozole.
99.2%· Janoshik
Hilma Biocare
Steroidal aromatase inactivator. Suicide AI for complete estrogen blockade.
99.0%· Janoshik
ZPHC
Arimidex 1mg tablets by ZPHC. Non-steroidal aromatase inhibitor.
99%+· ZPHC
For laboratory research only. Not for human consumption.
Resellers, laboratories and publishers: apply for partner pricing, volume terms and a dedicated representative.
Research use only. All products are sold strictly for in-vitro and laboratory research. Not for human consumption, veterinary use, diagnosis, treatment or prevention of any disease. Products sold by JuicedPharma are not medicines. By ordering you confirm you are a qualified person buying for research in compliance with applicable regulations. Full disclaimer